目的:我们旨在评估耐碳青霉烯类肠杆菌(CRE)定植压力和碳青霉烯类暴露与获得产碳青霉烯酶肠杆菌(CPE)和非产碳青霉烯酶CRE(非CP-CRE)之间的关联。
方法:我们在RambamHealthCareCampus进行了平行1:2匹配的病例对照研究,以色列从2014年1月至2017年6月。病例包括所有在医院内获得CPE或非CP-CRE的成年人。对照组为住院患者,筛查时CRE阴性,年龄相匹配,住院分类和CRE筛查前90天的住院天数。感兴趣的暴露是高CRE定殖压力,定义为采集前并发患者部门中CRE携带者的比例高于中位数,和碳青霉烯暴露,评估为治疗天数。使用条件逻辑回归分析CPE和非CP-CRE。
结果:总计,包括1058例患者:278例CPE和75例非CP-CRE病例。与556和149个控件相匹配,分别。高CRE定植压力与CPE获取相关,校正比值比(aOR)2.6(95CI1.69-4.02),但碳青霉烯治疗的持续时间不是(aOR1.004,95CI0.98-1.03,一天增加)。碳青霉烯治疗持续时间与非CP-CRE获得显著相关,OR每天1.07(95CI1.03-1.11)。与非CP-CRE相比,在CPE的流行病学获取调查中发现源患者的频率明显更高(107/240,44.6%vs.18/64,分别为28.1%,p=0.017)结论:CPE采集与水平传输相关,而非CP-CRE与碳青霉烯暴露有关。采购任务驱动因素的差异为预防感染的努力量身定制。
OBJECTIVE: We aimed to assess the association between carbapenem-resistant Enterobacterales (CRE)
colonization pressure and carbapenem exposure and acquisition of carbapenemase-producing Enterobacterales (CPE) and non-carbapenemase-producing carbapenem-resistant Enterobacterales (non-CP-CRE).
METHODS: We conducted a parallel 1:2 matched
case-control study at Rambam Health Care Campus, Israel, from January 2014 to June 2017. The cases included all adults who acquired CPE or non-CP-CRE in hospital. The controls were hospitalized patients who were negative for CRE on screening and matched by age, hospitalization division and the number of hospitalization days 90 days prior to CRE screening. The exposures of interest were high CRE
colonization pressure, defined as a higher-than-median proportion of CRE carriers in the concurrent patient\'s department before acquisition, and carbapenem exposure, assessed as days of treatment. Conditional logistic regression was used for analyses of CPE and non-CP-CRE.
RESULTS: In total, 1058 patients were included: 278 CPE and 75 non-CP-CRE cases, matched to 556 and 149 controls, respectively. High CRE
colonization pressure was associated with CPE acquisition (adjusted odds ratio [aOR], 2.6; 95% CI, 1.69-4.02); however, the duration of carbapenem treatment was not (aOR, 1.004; 95% CI, 0.98-1.03; 1-day increment). The duration of carbapenem treatment was significantly associated with non-CP-CRE acquisition (aOR per day, 1.07; 95% CI, 1.03-1.11). A source patient was identified significantly more frequently in epidemiological acquisition investigations of CPE than in those of non-CP-CRE (107/240, 44.6% vs. 18/64, 28.1%, respectively; p 0.017).
CONCLUSIONS: CPE acquisition was associated with horizontal transmission, whereas non-CP-CRE was associated with carbapenem exposure. Differences in the drivers of acquisition mandate tailored infection prevention efforts.